Cost of illness of chronic kidney disease in Lebanon: from the societal and third-party payer perspectives

• DOI: 10.1186/s12913-022-07936-0
• Publication Date: 2022-05-02T18:02:42Z
• Authors: Mabel Aoun; Elie Helou; Ghassan Sleilaty; Rony M. Zeenny; Dania Chelala
• Keywords: Nephrology; Health administration

Chronic kidney disease (CKD) is the 12th leading cause of death worldwide. Cost-of-illness studies CKD are scarce in developing countries. This study aims to estimate cost illness all stages Lebanon, from early until dialysis and transplantation. The secondary objective identify factors related highest financial burden.This a cross-sectional patients who presented two nephrology clinics during November 2020. Their medical administrative records were reviewed for collection demographics, characteristics, direct costs (medications, diagnostic tests, hospitalizations, inpatient care, outpatient care), non-medical (transportation) indirect (productivity losses) one year. Kruskal Wallis test was used compare between different categories. Logistic regression analysis evaluate risk associated with costs.The sample included 102 non-dialysis patients, 40 hemodialysis, 8 peritoneal 10 transplant patients. mean age 66.74 ± 15.36 years, 57.5% males 42.5% diabetics. total median per year across categories assessed be 7,217,500 Lebanese Pounds (3,750,000-35,535,250; 1 $USD = 1515 LBP 2019) societal perspective 5,685,500 (2,281,750- 32,386,500) third-party payer perspective. Statistical showed higher hemodialysis (p < 0.001), medications 0.001) technique modality 0.001). In sub-analysis vintage negatively correlated (r -0.391, p 0.013); found diabetes as factor (OR 2.3; 95%CI: 0.638,8.538; 0.201). subcategory CKD-ND 0.323, 0.001); coronary artery significantly 2.4; 1.083,5.396; 0.031; OR 3.7; 1.535,8.938; 0.004).This high burden compared It revealed Health policies should target interventions that prevent end-stage encourage